# OnCo record bicara-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/bicara-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "bicara-therapeutics" ;
  schema:name "Bicara Therapeutics"@en ;
  schema:description "Bicara's lead drug, ficerafusp alfa, is a two-in-one antibody that blocks the EGFR growth signal on head and neck cancer cells while also soaking up TGF-beta, a molecule tumours use to suppress immune attack. It is in a pivotal trial with pembrolizumab in head and neck cancer."@en ;
  schema:url <https://onco.cc/companies/bicara-therapeutics/>, <https://www.bicara.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.bicara.com/>, <https://www.sec.gov/Archives/edgar/data/2023658/000162828026055500/projectwaystar-2q26earning.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/ficerafusp-alfa/> ;
  onco:trials <https://onco.cc/trials/nct07807163/> .